Novo Nordisk presents four new analyses on oral semaglutide 25 mg at ObesityWeek 2025
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
